Nektar Therapeutics’s recent filing unveils that its Chief R&D Officer Zalevsky Jonathan unloaded Company’s shares for reported $10403.0 on Feb 19 ’25. In the deal valued at $1.01 per share,10,300 shares were sold. As a result of this transaction, Zalevsky Jonathan now holds 316,604 shares worth roughly $0.27 million.
Then, Wilson Mark Andrew sold 11,040 shares, generating $11,150 in total proceeds. Upon selling the shares at $1.01, the Chief Legal Officer now owns 324,292 shares.
Before that, ROBIN HOWARD W sold 23,774 shares. Nektar Therapeutics shares valued at $24,012 were divested by the President & CEO at a price of $1.01 per share. As a result of the transaction, ROBIN HOWARD W now holds 1,086,901 shares, worth roughly $0.92 million.
B. Riley Securities initiated its Nektar Therapeutics [NKTR] rating to a Buy in a research note published on January 08, 2025; the price target was $4. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who began to cover the stock in early December with a ‘”a Buy”‘ rating. Piper Sandler began covering NKTR with “an Overweight” recommendation on November 04, 2024.
Price Performance Review of NKTR
On Friday, Nektar Therapeutics [NASDAQ:NKTR] saw its stock fall -9.35% to $0.85. Over the last five days, the stock has lost -14.00%. Nektar Therapeutics shares have fallen nearly -9.14% since the year began. Nevertheless, the stocks have risen 22.46% over the past one year. While a 52-week high of $1.93 was reached on 01/07/25, a 52-week low of $0.63 was recorded on 02/12/25. SMA at 50 days reached $0.9182, while 200 days put it at $1.2033.
Levels Of Support And Resistance For NKTR Stock
The 24-hour chart illustrates a support level at 0.8020, which if violated will result in even more drops to 0.7591. On the upside, there is a resistance level at 0.9180. A further resistance level may holdings at 0.9911. The Relative Strength Index (RSI) on the 14-day chart is 46.92, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.0771, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 54.65%. Stochastics %K at 60.78% indicates the stock is a holding.
The most recent change occurred on June 28, 2024 when Rodman & Renshaw began covering the stock and recommended ‘”a Buy”‘ rating along with a $2 price target.
